Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement
AI-as-a-Service applications will make AI virtual CFO and COO for SMEsPublic-private collaboration in regulatory sandboxes help to provide clarity and certainty when it comes to new technology like tokenisation and AI
Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/

Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025.
“We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025.
Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassador (Climate Action), Singapore & Former Managing Director, Monetary Authority of Singapore, GFTN, and Dr. Razeen Sally who moderated the panel.
From Agentic Payment to Agentic Finance: A Virtual CFO, and COO for SMEs
On the consumer front, Jing expects the rise of personalised AI financial managers and advisors. On the business front, “Agentic payment is one of the most important forces driving agentic commerce and agentic systems,” Jing said. Ant will focus on democratising AI for SMEs at a time when small businesses engaged in global trade face increasingly complex payment and risk environments.
“Many SMEs may not have sophisticated digital skills or a large workforce to support them in doing business, and this is where AI agents can really play a role in helping them to navigate the landscape,” Jing said.
Antom, the merchant payment and digitisation services arm of Ant International, is using Antom Copilot to support payment integration, merchant onboarding, risk management settings, and chargeback response. Copilot cuts payment integration time by over 90%, boosts chargeback winning rates by 3 percentage points, and shortens chargeback resolution time by 46 percent.
During the Singapore FinTech Festival 2025, Antom also launched EPOS360, an app that brings point-of-sale (POS) system, payments, banking, lending, and growth support together to help micro, small and medium‑sized enterprises (MSMEs) move from setup to scale efficiently.
“Agentic AI will act like your COO, your CFO. They are stepping in as virtual financial and operational planners and implementers for SMEs, enabling them to compete globally,” Jing said.
He added that the rise of agentic payments and multi-agent systems are already on track, where autonomous AI agents collaborate to execute complex end-to-end transactions.
Collaboration with MAS on AI and Blockchain is an Exemplar of Public-Private Collaboration
“The tokenisation of money that enables global real-time settlement across borders will be particularly beneficial to SMEs and companies doing global trade,” Jing said. “On such important projects, it is necessary to have policy leadership from regulators like the Monetary Authority of Singapore, who provides institutional clarity and brings together an industry ecosystem of collaboration.”
Ant International’s deep collaboration with the Monetary Authority of Singapore (MAS) through key initiatives like Project Guardian and PathFin.ai sets an exemplary model of public-private partnership, especially when blockchain and AI have emerged as global themes.
“We are honoured to participate in the Monetary Authority of Singapore’s regulatory sandboxes. They provide the clarity and certainty needed to responsibly deploy cutting-edge technologies while managing risks,” said Jing. “This new technology is up and coming, we cannot shy away from it. Instead, the right way is to harness the technology to get the benefits while keeping in mind the potential risks and challenges.”
Under Project Guardian, Ant International has contributed to pilot efforts in tokenised money and cross-border settlements, demonstrating how real-time, transparent and credible blockchain-based payments can benefit SMEs engaged in global trade.
Through MAS’ PathFin.ai programme, Ant International is also actively engaging in knowledge exchange on AI implementations. Jing highlighted Ant International’s Falcon Time-Series Transformer (TST) Model — an 8.5-billion-parameter AI model designed for FX and liquidity forecasting. The model has significantly improved accuracy in predicting cash flow and liquidity, helping businesses reduce hedging costs in today’s volatile global economy.
“Through participating in sandboxes, we see benefits and opportunities to improve our products before rolling them out. It has really been a pleasure to be part of that – MAS is taking a very proactive role and it’s enormously valuable,” said Jing.
Ant International, which became independent in 2024, is headquartered in Singapore. The company now collaborates with over 1,400 institutional partners and provides global payment, settlement and digitisation services to 150 million merchants, and a network of global wallets and national QR schemes that together serve over 1.8 billion consumer accounts.
—END—
About Ant International
With headquarters in Singapore and main operations across Asia, Europe, the Middle East and Latin America, Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, our unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20251114239737/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom